Heart Valve Disease, Older Than 18-years-old, Without Any Liver or Kidney Diseases
Conditions
Keywords
warfarin, Chinese patients, heart valve replacement
Brief summary
To value the accuracy of the dosing algorithm published by the International Warfarin Pharmacogenetics Consortium in Chinese patients after heart valve replacement. To value the accuracy of warfarin pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.
Detailed description
The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium hadn't been verifying by a standard randomized prospective study in Chinese patients after heart valve replacement. And, warfarin will affect people's coagulation, so that probably increase the drainage. We'll analyse the interaction of patients' PT-INR or drainge and oral warfarin dosing.
Interventions
GENETICCYP2C9;VKORC1
Sponsors
Guangdong Provincial People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
atrial fibrillation * atrial fibrillation * heart valve replacement * VTE
Exclusion criteria
* severe liver or kidney diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The perccentage of time that the INR was in the therapeutic range | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| all drainage fluid of every patient | 1 week after operation |
Countries
China
Contacts
Primary ContactChen Yongbin, master
Outcome results
None listed